Ad
related to: missed one dose of simvastatin three
Search results
Results From The WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred. No mutagenic effects were seen in assays.
Cardiovascular agents generally have narrow therapeutic indices, implying that small differences in dose or blood concentration may give rise to adverse drug reactions. [45] Serious acute toxicity may result from accidental, intentional or iatrogenic overdose. [46] Therefore, patients need to be aware of any unusual and serious side effects.
In the United States, only the Johnson & Johnson COVID-19 vaccine is a “one-and-done” deal. U.S. clinical trials found that the one-dose regimen was 74.4 percent effective at protecting ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
The maximum semaglutide dose for weight loss is 2.4 milligrams (mg) per week. Your healthcare provider will start you on a lower weekly dose and gradually increase it over time.
Nelson's execution is the second in the U.S. this year and the first of four scheduled in Texas over the next three months. Fox News' Louis Casiano and the Associated Press contributed to this report.
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]